35 participants
A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2021-08-06
- Start Date:
- 2021-01-21
- Completion:
- 2022-12-01
Conditions
- Unresectable Stage III NSCLC
Interventions
- DRUG
- RADIATION
No Results Yet